Centers for Disease Control and Prevention

National Center for Emerging and Zoonotic Infectious Diseases

ACIP Dengue Vaccines Work Group

Wilbur Chen, MD, MSc

ACIP Member and Workgroup Chair

Advisory Committee on Immunization Practices

ACIP Meeting June 22, 2023
▪ DENV-1, 2, 3, 4

• Lifelong DENV type-specific 

immunity

• Short-term cross-immunity (~1–2 

years)

• A second dengue infection is the 

most important risk factor for 

severe dengue

▪ Dengue is the most common 

mosquito-borne virus globally

Dengue Virus
DengvaxiaTM

and previous 

dengue 

infection

Clinical trials found different outcomes after 

DengvaxiaTM vaccination among children with and 

without previous dengue infection.

• Children without previous dengue infection had a 

higher risk for hospitalization and severe dengue if 

they were vaccinated and then had a DENV infection.

• Children with previous dengue infection were 

protected from hospitalization and severe dengue if 

they were vaccinated with DengvaxiaTM.
DengvaxiaTM ACIP Recommendation June 2021

Three doses of Dengvaxia are indicated 

for the prevention of dengue disease 

caused by dengue virus serotypes 1, 2, 

3, and 4 in people 9–16 years old with:

• laboratory confirmation of previous 

dengue virus infection

AND

• living in endemic areas.
Previous Presentations to ACIP on TAK-003

Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov

2022 2023

• Takeda dengue 

vaccine safety and 

efficacy presentation

• Workgroup summary 

and interpretation

• Dengue epidemiology

• Review of Sanofi dengue 

vaccine and ACIP 

recommendation
Presentations Today

Introduction of policy questions for TAK-003

• Dr. Alfonso Hernandez, CDC, NCEZID, DVBD

Cost effectiveness analysis and health impacts of routine vaccination 

with TAK-003 dengue vaccine in Puerto Rico

• Dr. Guido España, Notre Dame

Summary of two economic models for dengue vaccine TAK-003 use in 

Puerto Rico

• Dr. RajReni Kaul, CDC

Partial evidence to recommendations framework for TAK-003

• Dr. Joshua Wong, CDC, NCEZID, DVBD
Future Presentations to ACIP on TAK-003

*Timeline subject to change

Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov

2022 2023

• Takeda dengue 

vaccine safety and 

efficacy presentation

• Workgroup summary 

and interpretation

• Policy questions

• Cost-effective (CE) analysis 

(CDC/Notre Dame)

• Comparison of CE models

• Partial EtR

• Dengue epidemiology

• Review of Sanofi dengue 

vaccine and ACIP 

recommendation

• Full EtR*

• Draft recommendation*

• Vote*
ACIP Dengue Vaccines Work Group

ACIP Members

• Wilbur Chen (Chair)

• Kathy Poehling

• Beth Bell

• Veronica McNally

CDC Co-Leads

• Gabriela Paz-Bailey

• Laura Adams

Ex Officio Members

• Kaitlyn Morabito (NIH)

• Ralph LeBlanc (FDA)

• Ihid Carneiro Leao (FDA)

• Kirk Prutzman (FDA)

• Srihari Seshadri (DOD)

• Liaison Representatives

• Elizabeth Barnett (AAP)

• Rob Schechter (AIM)

Consultants

• Edwin Asturias

• Robert Atmar

• Alan Barrett

• Iris Cardona

• Anna Durbin

• Tony Marfin

• Kristen Pierce

• Anita Shet

CDC Contributors

• Joshua Wong

• Nicole Medina

• Mimi Eckert

• Rachel Eidex

• Alfonso Hernandez

• Susan Hills

• Terri Hyde

• Mike McNeil

• Jorge Munoz

• Erin Staples

• Cindy Weinbaum

• Rita Helfand